Introduction
peripheral T-cell lymphoma, Cancer
PERIPHERAL T-CELL LYMPHOMA, CANCER
Edited by: Narendranath Epperla, The Ohio State University, United StatesReviewed by: Alejandro Martín García-Sancho, University Hospital of Salamanca, Spain; Khalil Saleh, Gustave Roussy Cancer Campus, France; Walter Hanel, The Ohio State University, United StatesThis article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in ImmunologyThe treatment for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) is suboptimal. This open-label, multicenter, single-arm study aimed to investigate the antitumor activity and safety of camrelizumab (a PD-1 blockade) plus apatinib (an antiangiogenic agent) for patients with r/r PTCL.